Acoltremon 0.003% ophthalmic solution in dry eye disease: a profile of its use
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
DeclarationsFunding The preparation of this review was not supported by any external funding.Authorship and conflict of interest K. Chen and H. A. Blair are salaried employees of Adis International Ltd/Springer Nature and declare no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability Not applicable.Additional information about this Adis Drug Review can be found here.AbstractAcoltremon (TRYPTYR®), a first-in-class, transient receptor potential melastatin 8 (TRPM8) thermoreceptor agonist formulated as a topical 0.003% ophthalmic solution, is approved in the USA for the treatment of dry eye disease (DED) and represents a promising new treatment option. Acoltremon 0.003% demonstrated statistically significant improvements in tear production in two pivotal phase 3 trials, as well as statistically significant improvements in patient-reported signs and symptoms of DED compared with vehicle in one of these trials. Acoltremon 0.003% displayed a rapid onset of activity, with improvements in tear production evident from day 1 and sustained throughout the duration of all trials. Acoltremon 0.003% was well tolerated, including over the longer term, with low rates of study discontinuation and an overall favorable safety profile.© Springer Nature Switzerland AG 2026
Fields of Study & Subjects
Ocular Surface and Contact Lens
Advanced Drug Delivery Systems
Salivary Gland Disorders and Functions
Publication details
- Journal / source
- Figshare
- Publication date
- 26 March 2026
- Language
- EN